Key result
ASSURE WCD achieves a false-positive shock alarm rate ~99% below the performance goal.
Why the study?
Wearable cardioverter defibrillators are limited by frequent false shock alarms from electrocardiogram noise and wear discomfort, motivating testing of a contemporary device designed to address these issues.
Does the ASSURE wearable cardioverter defibrillator have a low false-positive shock alarm rate in patients with LVEF ≤40% and an active ICD?
Observational (n=130)
Does the ASSURE wearable cardioverter defibrillator have a low false-positive shock alarm rate in patients with LVEF ≤40% and an active ICD?
Answers are grounded in this paper and cite their sources.
The ASSURE wearable cardioverter defibrillator demonstrated a very low false-positive shock alarm rate and high patient compliance with no serious adverse events.
Introduction A wearable cardioverter defibrillator (WCD) is indicated in appropriate patients to reduce the risk for sudden cardiac death. Challenges for patients wearing a WCD have been frequent false shock alarms primarily due to electrocardiogram noise and wear discomfort. The objective of this study was to test a contemporary WCD designed for reduced false shock alarms and improved comfort. Methods One hundred and thirty patients with left ventricular ejection fraction ≤40% and an active implantable cardioverter defibrillator (ICD) were fitted with the ASSURE WCD (Kestra Medical Technologies) and followed for 30 days. WCD detection was enabled and shock alarm markers recorded, but shocks and shock alarms were disabled. All WCD episodes and ICD ventricular tachycardia/ventricular fibrillation (VT/VF) episodes were adjudicated. The primary endpoint was the false‐positive shock alarm rate with a performance goal of 1 every 3.4 days (0.29 per patient‐day). Results Of 163 WCD episodes, 4 were VT/VF and 159 non‐VT/VF (121 rhythms with noise, 32 uncertain with noise, 6 atrial flutter without noise). Only three false‐positive shock alarm markers were recorded; one false‐positive shock alarm every 1333 patient‐days (0.00075 per patient‐day, 95% confidence interval: 0.00015–0.00361; p < .001). No ICD recorded VT/VF episodes meeting WCD detection criteria (≥170 bpm for ≥20 s) were missed by the WCD during 3501 patient‐days of use. Median wear was 31.0 days (interquartile range [IQR] 2.0) and median daily use 23.0 h (IQR 1.7). Adverse events were mostly mild: skin irritation (19.4%) and musculoskeletal discomfort (8.5%). Conclusion The ASSURE WCD demonstrated a low false‐positive shock alarm rate, low patient‐reported discomfort, and no serious adverse events.
No takes yet. Share an insight, caveat, or question.
Poole et al. (2022) conducted an observational in Left ventricular ejection fraction ≤40% and an active implantable cardioverter defibrillator (n=130). ASSURE wearable cardioverter defibrillator vs. Performance goal was evaluated on False-positive shock alarm rate (95% CI 0.00015-0.00361, p=<0.001). The ASSURE wearable cardioverter defibrillator demonstrated a low false-positive shock alarm rate of 0.00075 per patient-day against a 0.29 performance goal.
Synapse has enriched 10 related papers. Consider them for comparative context: